Comparison of Two Routes of Administration of a Multimodal Analgesic Protocol in Postoperative Cesarean Section

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (112 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: womenfailurepainheartstatus
  Phrases that lowered it: gastrointestinalphysicaldisorderscolitiscrohn
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Phase: 2/3 (raises risk) · Design
• Drug's FAERS reports with a death: 16.7% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 79.5% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 121243 (lowers risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Application of Transversus Abdominus Plain Block, Local Subcutaneous Injection and IV Nalbuphine NCT05276206 · started 2022 · scored riskier than 8% of active trials completed
• Management Of Pain After Cesarean Trial NCT03929640 · started 2019 · scored riskier than 51% of active trials terminated
• Effect of Intraoperative Intravenous Lidocaine on Postoperative Pain and Return of Bowel Function After Cesarean Sections NCT06433713 · started 2023 · scored riskier than 17% of active trials completed
• Ropivacaine Through Continuous Infusion Versus Epidural Morphine for Postoperative Analgesia After Emergency Cesarean Section NCT02410317 · started 2015 · scored riskier than 78% of active trials completed
• Hemodynamic Protection of Preoperative Ondansetron 15 Minutes Before Spinal Anaesthesia in Caesarean Section NCT04140058 · started 2016 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.